Medtronic (MDT) Stock Looks Fairly Valued On Cash Flow But Cheap On Earnings
Medtronic stock has fallen about 21.2% over the past five years, yet current valuation checks and an intrinsic value estimate based on a Discounted Cash Flow (DCF) approach suggest the shares now sit close to what that cash flow model implies is fair value, while market multiples screen the company as undervalued.
- The roughly 21.2% share price decline over five years means long term holders have not been rewarded, which puts extra focus on whether today’s price fairly reflects Medtronic’s earnings power and balance sheet.
- Restructuring and portfolio refocusing, including a spin off of the diabetes unit and a stronger push in higher margin cardiovascular and neuroscience products that use AI features, can support sentiment on growth, although execution risks around these shifts may weigh on how much investors are willing to pay for the stock.
- Medtronic scores 4 out of 6 on the valuation checks, which points to a mixed picture rather than a clear bargain or an obviously expensive stock.
The issue now is whether Medtronic’s current price leaves enough upside relative to its intrinsic value and market multiples to compensate investors who are weighing the recent share price record against the company’s progress.
Does Medtronic Look Fairly Valued on Cash Flow?
The Discounted Cash Flow (DCF) method estimates what Medtronic is worth today based on the cash it is expected to generate for shareholders. Medtronic produced about $5.4b in free cash flow over the latest twelve months, and the model assumes these cash flows continue to grow rather than contract over the coming decade.
On those assumptions, the DCF model points to an estimated intrinsic value of about $90 per share. That sits only slightly above the current share price, implying Medtronic screens roughly fairly valued with a modest 4.7% discount. Because the recent restructuring, including the diabetes spin off and refocus on higher margin cardiovascular and neuroscience products, is already well publicised, the small discount suggests the market is not giving much extra credit for these moves.
Overall, the DCF workup indicates Medtronic stock looks about fairly valued, with only a small gap between price and estimated intrinsic value.
Medtronic is fairly valued according to our Discounted Cash Flow (DCF), but this can change at a moment's notice. Track the value in your watchlist or portfolio and be alerted on when to act.
Is Medtronic Still Cheap on Earnings?
P/E is a useful cross check for Medtronic because earnings remain a key driver of how investors look at large, established medical equipment companies. Medtronic currently trades on a P/E of about 22.9x, which sits below the Medical Equipment industry average of roughly 28.1x and the peer group average of about 32.7x.
The fair P/E ratio implied by the model is about 30.5x, which is closer to those peer levels than to the current market multiple. That gap suggests investors are paying a lower price for each dollar of Medtronic’s earnings than the model would indicate given its size, margins and industry position. The discount on P/E is consistent with the message from the DCF work, which also did not flag Medtronic as expensive.
Taken together, the P/E comparison indicates Medtronic stock may be undervalued on this earnings multiple.
See what the numbers say about this price — find out in our valuation breakdown.
The Medtronic Narrative: What Would Justify Today's Price?
Simply Wall St Narratives pick up where the Medtronic valuation work leaves off by spelling out which paths for Medtronic's growth, margins and earnings would need to hold for the stock to be worth meaningfully more or less than today’s price. These narratives sit on the company’s Community page. Rather than relying on a single multiple or model output, each narrative lays out the assumptions behind its view of fair value so you can compare them with Medtronic's actual results over time.
Community views on Medtronic sit far apart, with one side focused on product momentum and the other stressing execution and valuation risk.
Bull case: 12% undervalued
"Medtronic's investments and breakthroughs in digital health technologies, robotics (Hugo), next-generation sensors, and AI-enabled ecosystems (e.g., spine AiBLE, advanced neuromodulation) align with industry-wide digital transformation and minimally invasive trends..."
Read the full Bull Case to see why Medtronic could be undervalued
Bear case: 10% overvalued
"This narrative explores a more pessimistic perspective on Medtronic compared to the consensus, based on a Fair Value that aligns with the bearish cohort of analysts..."
Read the full Bear Case to see why Medtronic could be overvalued
Do you think there's more to the story for Medtronic? Head over to our Community to see what others are saying!
The Bottom Line
For Medtronic, the Discounted Cash Flow (DCF) work points to an intrinsic value only modestly above the current share price, while the P/E comparison suggests the stock trades on an undervalued multiple relative to peers. Taken together, these signals indicate a company that does not appear obviously mispriced but may offer some valuation appeal if its earnings profile holds up.
The key variable from here is whether Medtronic can execute on its portfolio reshaping and higher-margin focus without meaningful stumbles. If that execution is successful, the current discount could appear more like an opportunity than a reflection of appropriately priced risk.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com